 2004 |
|
 December 9 |
AnGes MG Selected by Pharmaceuticals and Medical Devices Agency for Research Grant
--Clinical trials are anticipated using NFκB decoy oligo therapeutic agent for atopic dermatitis-- |
| November 24 |
Phase I clinical trials of HGF plasmid for the treatment of Ischemic Heart Disease (IHD) underway in the United States
-- Clinical trials of HGF plasmid for both peripheral arterial disease (PAD) and IHD -- |
| November 9 |
AnGes MG Joins Hands with ImmunoFrontier
-- Transfer of Patent Rights for Cancer DNA Vaccine -- |
| September 1 |
Announcement: Relocation of Headquarters and Research Center
-- Integration of Headquarters and Research Center to Saito -- |
| July 26 |
GenomIdea's Joint Development with Mitsubishi Space Software Bears Fruit
-- Development of a New Drug Design System for the Next-generation Nucleic acid Medicine "siRNA" Completed -- |
| July 12 |
The U.S. Food and Drug Administration (FDA) has given the go-ahead for a clinical trial investigating AnGes' HGF plasmid for the treatment of ischemic heart disease (IHD). This U.S. study will be the first clinical investigation of HGF plasmid for IHD. |
| June 30 |
AnGes MG to Join the University of Tokyo (Hospital) Project:"22nd Century Medical Center" (tentative name)
-Establishes joint research program on forefront clinical medicine, including development of genetic medication and cell remediation medicines.- |
| June 28 |
Launch of Shimadzu Corporation and AnGes MG Joint Research Project
-To develop a new therapy for refractory dermatosis with nucleic acid medicines administered via the needleless pressure injector "Shima JET." - |
| June 7 |
AnGes MG Forms a Business Alliance with NeoChemir.
Expands treatments of ischemic diseases through introduction of a new carbon dioxide generating wound dressing material |
| March 23 |
AnGes MG Seeks Faster New Drug Approval-Applications Via Document Management System
-Infocom to be systems integrator for application submission system- |
| March 17 |
AnGes MG Expanding Its US Presence
-Licensing activities now in full-swing on the bioventure-rich US West Coast- |
| March 17 |
Commencement of Clinical trials for HGF Genetic Medicine in Japan
-The first multi-centered double-blind trial for genetic medicine in Japan- |
| February 26 |
Investigational New Drug (IND) application filedwith the USFDA for HGF genetic medicine against ischemic heart disease
- Peripheral arterial disease and ischemic heart disease related clinical trials in the USA - |
| February 20 |
AnGes MG appoints new director |
| February 2 |
AnGes MG and Gene Design Inc. embark on joint development
of next-generation decoy nucleotides as part of their
push into the field of systemic diseases including cancer and IBD |
 |
|
